Tirzepatide

Reference content. Not medical advice. Decisions about use require qualified medical supervision. Tirzepatide is FDA- and EMA-approved for T2D and chronic weight management; consumer access is via prescription (brand Mounjaro / Zepbound or, in narrow personalized cases, 503A compounding) — mass-compounded supply effectively ended in the US on 19 March 2025.

---

1. Identity

INN: Tirzepatide Research code: LY3298176 CAS: 2023788-19-2 [Academic secondary source — PubChem CID 156588324] Molecular formula / weight: C₂₂₅H₃₄₈N₄₈O₆₈; ~4,813.5 Da (average) Class: Dual GIP / GLP-1 receptor co-agonist; 39-aa synthetic peptide carrying a C20 fatty-diacid moiety for albumin binding; biased agonist at GIPR (reduced β-arrestin recruitment vs native GIP), balanced full agonist at GLP-1R [Peer-reviewed preclinical study — Coskun 2018; Willard 2020] ⚠️ Half-life: ~5 days (supports once-weekly subcutaneous dosing) [Regulatory document — FDA NDA 215866 (Mounjaro); NDA 217806 (Zepbound)] Brand names: Mounjaro (T2D); Zepbound (chronic weight management; moderate-to-severe OSA in obese adults, US)

2. History and Development

First-in-human Phase 1 in 2017–2018; Phase 2 dose-ranging in T2D 2018 [Frias Lancet 2018] ⚠️. SURPASS Phase 3 program in T2D ran 2019–2022; FDA approval as Mounjaro on 13 May 2022 [Regulatory document — FDA NDA 215866]; EMA marketing authorization 15 September 2022 [EMA EPAR EMEA/H/C/005620]. SURMOUNT-1 obesity Phase 3 published in NEJM 2022 [Jastreboff NEJM 2022]; FDA approval of Zepbound for chronic weight management 8 November 2023 [Regulatory document — FDA NDA 217806]. 20 December 2024: FDA approves Zepbound for moderate-to-severe OSA in obese adults — first drug approval for OSA in any population. 19 December 2024: FDA declares tirzepatide injection shortage resolved [Regulatory document — FDA Declaratory Order]; enforcement discretion for 503A compounders ended 18 February 2025 and for 503B outsourcing facilities 19 March 2025. 7 May 2025: N.D. Tex. denies preliminary injunction in Outsourcing Facilities Association v. FDA (4:24-cv-00953); mass-compounding effectively ends. 11 May 2025: SURMOUNT-5 head-to-head vs semaglutide 2.4 mg published in NEJM [Aronne NEJM 2025] ⚠️. May 2025: Lilly withdraws US HFpEF sNDA after FDA requests a confirmatory trial [Press release]. 17 December 2025: SURPASS-CVOT peer-reviewed publication in NEJM [Nicholls NEJM 2025] ⚠️.

3. Mechanism of Action

Demonstrated (human). Dual full agonism at GLP-1R and biased agonism at GIPR, validated in human-cell systems and translated to PK/PD [Peer-reviewed preclinical/translational — Coskun 2018; Willard 2020] ⚠️. Augments first- and second-phase glucose-stimulated insulin secretion and suppresses inappropriate glucagon; slows gastric emptying (acute > chronic, with tachyphylaxis on chronic dosing); reduces ad libitum energy intake in human meal-challenge studies [Peer-reviewed human study — Heise Lancet D&E 2022]. SUMMIT mechanistic secondary analysis at 52 weeks: systolic BP −5 mmHg, estimated plasma volume −0.58 L, hsCRP −37.2% — consistent with a cardiometabolic / anti-inflammatory action [Peer-reviewed human study — Borlaug Nat Med 2024] ⚠️. DXA substudies of SURMOUNT-1 indicate predominantly fat-mass loss with proportional lean-mass reduction approximately consistent with diet-induced weight loss [Peer-reviewed human study — Jastreboff 2022 supplementary] ⚠️.

Proposed / preclinical (not confirmed in humans). Cryo-EM at 2.5–3.0 Å of tirzepatide-bound GLP-1R and GIPR complexes resolves distinct active-state conformations [Sun Cell 2022]. Hypothalamic POMC/AgRP modulation and area-postrema-mediated satiety in rodent and non-human-primate models [Samms JCI 2021]. Brown/beige adipose activation in rodent obesity models — not replicated in humans. Direct cardioprotective effects independent of weight loss proposed from a murine angiotensin-II HF model with EF preservation vs liraglutide [Sayour Cardiovasc Diabetol 2025].

4. Regulatory Status

Authority	T2D	Obesity	OSA	Other
FDA (US)	Approved 2022-05-13	Approved 2023-11-08	Approved 2024-12-20	HFpEF sNDA withdrawn 2025-05
EMA (EU)	Approved 2022-09-15	Approved 2023-12	Under review	—
MHRA (UK)	Approved 2022-09	Approved 2023-11	Pending	NICE TA restrictions on weight
PMDA (Japan)	Approved 2022-09	Approved 2024	Pending	—
NMPA (China)	Approved 2024-05	Approved 2024-07	Pending	—
MFDS (Korea)	Approved 2023	Approved 2024	Pending	—
TGA (Australia)	Approved 2022-12	Approved 2024-08	Pending	—
Health Canada	Approved 2022-11	Approved 2024-05	Pending	—
GRLS (Russia)	Not registered	Not registered	—	—
WHO EML	Not listed (2026 update)	Not listed	—	—

WADA 2026: Tirzepatide is not prohibited. Added to the 2026 Monitoring Program effective 2026-01-01 alongside semaglutide; markers tracked in- and out-of-competition [Regulatory document — WADA 2026 Monitoring Program, September 2025].

5. Formulations and Routes

• Single-dose prefilled autoinjector pens (original presentation): weekly SC; 2.5 mg start dose escalated by 2.5 mg every 4 weeks to maximum tolerated dose (10, 12.5, or 15 mg).
• KwikPen multidose pen (2024): 0.5 mL prefilled multidose pen at single strengths (2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg), introduced to expand supply during the shortage.
• Single-dose vials (Zepbound 2.5 mg and 5 mg): launched August 2024 in the US at a reduced price-point.
• Investigational oral tirzepatide: No Phase 3 data published as of 2026-05-13; Lilly’s oral GLP-1 program centers on the distinct small-molecule orforglipron, not tirzepatide.
• Longer-interval (Q2W / monthly) dosing: No peer-reviewed Phase 2/3 data identified as of 2026-05-13.
• Compounded tirzepatide: No longer legally available via 503A or 503B mass-compounding in the US after 2025-03-19; narrow individualized 503A exceptions remain only with documented clinical necessity (e.g., excipient allergy). “Personalized” 503A formulations with added niacinamide (B3) or pyridoxine (B6) are marketed as legally distinct “non-copies” and remain in commercial supply; their regulatory durability is contested (Lilly v. Alderwood, W.D. Wash. 2:24-cv-00878, survived motion to dismiss 2025-03-07) [Regulatory document — FDA Declaratory Order 2024-12-19; OFA v. FDA, N.D. Tex., 2025-05-07].

6. Preclinical Evidence

• Receptor pharmacology: biased agonism at human GIPR (reduced β-arrestin recruitment vs native GIP); balanced full agonism at GLP-1R [Coskun 2018; Willard 2020].
• DIO mouse and ZDF rat models: dose-dependent reductions in body weight, food intake, HbA1c, with improvements in islet function [Coskun 2018].
• MASH preclinical models: hepatic triglyceride and inflammatory marker reductions in CCl4 and choline-deficient–high-fat models [Hartman 2020].
• Cardiovascular preclinical: angiotensin-II–induced HF in Balb/c mice — preserved EF and improved survival vs liraglutide [Sayour 2025].
• Cryo-EM: tirzepatide–GLP-1R and tirzepatide–GIPR complexes [Sun Cell 2022].

7. Clinical Evidence

Cochrane SR specific to tirzepatide: none as of 2026-05-13. Multiple peer-reviewed meta-analyses (Khawaji J Obes 2025; Tian Front Endocrinol 2025; MDPI Pharmaceuticals 2025; PMC12263181) confirm class-leading weight-loss magnitude vs placebo and vs GLP-1 mono-agonists.

Phase 3 — T2D (SURPASS, all Lilly-funded ⚠️):

• SURPASS-1 (placebo, n=478, 40 wk): HbA1c −1.87 to −2.07%; weight −7.0 to −9.5 kg [Rosenstock Lancet 2021].
• SURPASS-2 (semaglutide 1 mg, n=1,879, 40 wk): tirzepatide superior on HbA1c (−2.01 to −2.30% vs −1.86%) and weight [Frías NEJM 2021].
• SURPASS-3 (insulin degludec, n=1,444, 52 wk): superior glycemic and weight outcomes [Ludvik Lancet 2021].
• SURPASS-4 (insulin glargine, CV-risk pop., n=2,002, 52 wk): superior; exploratory MACE-4 HR 0.74 [Del Prato Lancet 2021].
• SURPASS-5 (placebo + glargine, n=475, 40 wk): add-on superior [Dahl JAMA 2022].
• SURPASS-AP-Combo and SURPASS-J-MONO: confirmatory in Asia-Pacific and Japanese populations.
• SURPASS-CVOT (dulaglutide 1.5 mg, n=13,165, median 4 y, NCT04255433): non-inferior MACE-3; numerical reductions in CV death (~8%) and all-cause mortality (~16%); greater HbA1c, weight, BP, lipid improvement; discontinuation due to AEs 13.3% vs 10.2% [Nicholls NEJM 2025;393:2409–2420; PMID 41406444] ⚠️.
• SURPASS-PEDS (T2D 10–18 y, n≈99, EASD 2025): primary HbA1c and BMI endpoints met; full manuscript pending [Conference / press release, not peer-reviewed] ⚠️.

Phase 3 — Obesity (SURMOUNT, all Lilly-funded ⚠️):

• SURMOUNT-1 (no T2D, n=2,539, 72 wk): weight −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% placebo [Jastreboff NEJM 2022].
• SURMOUNT-2 (T2D + obesity, n=938, 72 wk): −12.8 to −14.7% vs −3.2% placebo [Garvey Lancet 2023].
• SURMOUNT-3 (after lifestyle run-in, n=579, 72 wk): additional −18.4% vs +2.5% placebo [Wadden Nat Med 2023].
• SURMOUNT-4 (withdrawal design, n=670, 88 wk): continuing tirzepatide +5.5% additional reduction vs +14.0% regain on placebo [Aronne JAMA 2024].
• SURMOUNT-5 (head-to-head semaglutide 2.4 mg, n=751, 72 wk): −20.2% tirzepatide vs −13.7% semaglutide (p<0.001); waist −18.4 vs −13.0 cm; greater proportion achieving ≥10–25% weight-loss thresholds [Aronne NEJM 2025;393:26–36] ⚠️.
• SURMOUNT-CN and SURMOUNT-J: confirmed efficacy in Chinese and Japanese populations.
• SURMOUNT-OSA (master protocol, two substudies, n=469, 52 wk): AHI reduction Study 1 (no PAP) −25.3 events/h vs −5.3; Study 2 (on PAP) −29.3 vs −5.5; ~50% achieved remission or mild OSA [Malhotra NEJM 2024;391:1193] ⚠️.
• SURMOUNT-MMO (n≈15,300, 5-point MACE composite, event-driven, expected ~2027-10): no readout as of 2026-05-13.
• SURMOUNT-MAINTAIN (dose-reduction strategy) and SURMOUNT-ADOLESCENTS-2 (12–17 y): no readouts.

MASH / liver — SYNERGY-NASH (Phase 2, n=190, NCT04166773): resolution of MASH without worsening fibrosis at 52 weeks: 51.8% (5 mg), 62.8% (10 mg), 73.3% (15 mg) vs 13.2% placebo [Loomba NEJM 2024;391:299–310] ⚠️. Phase 3 ongoing.

HFpEF — SUMMIT (Phase 3, n=731 obese HFpEF, mean BMI >38, NCT04847557): composite of CV death or worsening HF events HR 0.62; 46% reduction in worsening HF events; KCCQ-CSS +6.9; 6MWD +18.3 m [Packer NEJM 2024] ⚠️. US sNDA withdrawn May 2025 after FDA requested confirmatory trial.

Real-world replication (largely independent): Aetion / Brigham trial-emulation showed semaglutide and tirzepatide produced similar cardiovascular benefit magnitudes in elevated-risk T2D + obesity [Krüger Nat Med 2026]. TriNetX cohorts and JACC Adv 2025 cohort replicate effects, consistent with later SURPASS-CVOT.

Industry funding and single-group dependency: All SURPASS and SURMOUNT pivotal trials are Lilly-funded ⚠️ — universal pattern for the drug class. The 🔴 single-group-dependency flag does not apply: pivotal evidence spans multiple academic investigators (Jastreboff, Aronne, Frías, Del Prato, Garvey, Wadden, Packer, Loomba, Malhotra, Nicholls), and independent RWE replication exists (Aetion, TriNetX). This separates tirzepatide from compounds like the Khavinson peptides where one research group dominates the evidence base.

7B. Community Evidence Layer

Driving subcommunities: Weight-loss seekers from r/Mounjaro and r/loseit drove first-wave optimization-audience adoption in Q1–Q2 2023 — not bodybuilders. Trigger was three converging forces: Peter Attia’s AMA #45 (March 2023, The Drive) framing lean-mass loss as the central concern; the SURMOUNT-1 22.5% headline at 15 mg; and the FDA placing tirzepatide on the shortage list, opening 503A and 503B compounding pharmacies to mass-produce vials at ~10% of brand price. Bodybuilders on Meso-Rx, AnabolicMinds, and ProMuscle came second (mid–late 2023), framing tirzepatide as a “no-jitter Clen replacement” for cutting cycles. Longevity optimizers (Attia / Huberman audiences) treated it as a metabolic-syndrome tool, not a geroprotector, and remained the most cautious cohort.

Trajectory: Declining-from-peak but stabilizing. The 2024 compounding bubble has burst — pre–March 2025 era of $200–400/mo compounded tirzepatide is over. Post-shortage migration has fragmented into three channels: brand Zepbound via LillyDirect single-dose vials at $349–549/mo; “personalized” 503A compounds with added B3/B6 marketed as legally distinct “non-copies” at ~$199–419/mo; and gray-market research-peptide vials labeled “for research only” at ~$2–8/mg of API. A parallel migration of cost-sensitive users to retatrutide is documented across r/Peptides and r/PeptideUmbrella late-2025 threads.

Codified protocols (community-named, sourced in Pass 2 file): Medical titration mirrors the label (2.5 → 15 mg over 16 weeks). Community-invented additions: (a) sub-2.5 mg microdosing (0.5–2 mg/wk) for users prioritizing food-noise suppression with reduced GI and lean-mass effects; (b) bodybuilder cutting blocks (2.5–7.5 mg/wk, 8–16 weeks, paired with TRT and HGH 2–4 IU); (c) maintenance off-ramps (5 mg → q2wk → q3wk → stop); (d) tirzepatide → retatrutide cross-over (taper 10 → 2.5 mg over 4 wk, start retatrutide 2 mg).

Widely-reported community effects beyond on-label endpoints: food noise suppression within 24–72 h of first dose (widespread); alcohol consumption reduction within 2–4 weeks (widespread); reduced nicotine, cannabis, and other addictive-behavior urges (common); split mood signal — half describe mood lift, half describe flattening / anhedonia (the anhedonia narrative is amplified disproportionately by a small number of pseudonymous Substack / X writers 🔴); inflammation / joint pain reduction (common, mostly attributed to weight loss).

Widely-reported community side effects beyond label AEs: “Ozempic face” / facial volume loss (widespread, attributed mostly to fat loss); sulfur burps at dose escalation (common, with megathread-codified Pepcid / ginger remedies); hair shedding 3–4 months in (common, attributed to nutrient deficits + rapid weight loss); rebound hunger and 30–60% regain within 6–12 months of discontinuation (widespread); “Ozempic babies” / unplanned pregnancies attributed to restored fertility + reduced oral-contraceptive absorption (common, community guidance: switch to non-oral contraception); vendor-specific underdosing of gray-market vials at 60–80% of label claim via Janoshik testing (occasional but persistent).

Community-internal dissent (not smoothed): Tirzepatide vs. semaglutide — dominant view favors tirzepatide on tolerability and effect; minority on r/Semaglutide and r/WegovyWeightLoss argues sema has the longer track record and cleaner CV data (SELECT). Compounded vs. brand — heated split after March 2025 deadlines between “compounded was always sketchy” purists and “503A personalized formulations are legal and equivalent” pragmatists; Lilly v. Alderwood and Dave Ricks’s enforcement statements are central. Microdosing legitimacy — endorsed by sub-2.5 mg users on r/tirzepatidecompound, contested as “vibes-based” and cost-cutting by mainstream r/Mounjaro voices. Use in BMI <27 — sharply split: Attia explicitly refuses to prescribe below BMI 27 in his practice; bodybuilding forums endorse aggressive off-label cutting in already-lean athletes. Muscle preservation — three camps: protein + resistance training is sufficient (Layne Norton); add TRT in older men (bodybuilding forums); add HGH / MK-677 (Ben Greenfield–adjacent fringe).

Vendor / supply landscape: Compounding pharmacies most-named on r/tirzepatidecompound and listing aggregators are Empower (Houston, 503A and 503B, PCAB-accredited), Hallandale (B3-added “non-copy” workaround), Strive, Olympia, Belmar, and Red Rock — all ⚠️ commercial. Telehealth → compound pipeline: Curex, Alloy, Noom Med, Brello Health, Eden, OnlineSemaglutide.org. Gray-market research vendors named on r/Peptides and r/PeptideUmbrella: Peptide Sciences, PureRawz, Amino Asylum, Limitless Life. Community quality-control practice: order multiple batches, send aliquots to Janoshik Analytical (Czech-based, dominant community-trusted third-party HPLC service — 🔴 single-lab dependency), and post the COA to subreddit megathreads. As of 28 February 2025, FDA logged 320+ adverse-event reports tied to compounded tirzepatide (versus 455 for compounded semaglutide), some traced to patient-side dosing errors but some to batch issues.

Full community evidence detail is in the Pass 2 file (project).

8. Safety Profile

Common AEs (>10%): Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain, injection-site reactions, fatigue [Regulatory document — FDA Zepbound and Mounjaro labels]. Most events mild-to-moderate, peaking during dose escalation. SURPASS-CVOT discontinuation due to AEs 13.3% vs 10.2% for dulaglutide [Nicholls NEJM 2025] ⚠️.

Boxed warning — thyroid C-cell tumours. US label retains the class boxed warning based on rodent medullary thyroid carcinoma data; contraindicated in patients with personal or family history of MTC or MEN2 [Regulatory document — FDA labels]. EMA framing is contraindication without “boxed” designation.

Other label warnings: Acute pancreatitis; gallbladder / biliary disease; severe GI adverse reactions; acute kidney injury (volume-depletion-mediated); hypoglycemia with concurrent sulfonylurea or insulin; hypersensitivity (including anaphylaxis and angioedema); diabetic retinopathy worsening with rapid glycemic improvement; pulmonary aspiration during procedures requiring deep sedation or general anaesthesia (ASA 2023 guidance reflected in 2024 label revisions).

Pharmacovigilance signals. NAION / ischemic optic neuropathy: FAERS Jan 2022 – Jun 2025 — 28 ION cases with tirzepatide as primary suspect; ROR 2.60 (95% CI 1.78–3.80), statistically significant disproportionality [PMC12774802 2025]. JAMA Netw Open 2025;8:e2526327 (Wang/Volkow/Kaelber/Xu): both semaglutide and tirzepatide associated with increased optic-nerve-disorder risk vs other antidiabetics in propensity-matched cohort; magnitude smaller for tirzepatide. FDA and EMA have not added formal NAION warnings as of 2026-05-13. Ileus / bowel obstruction: GI motility signal at class level. Pancreato-biliary: Cholelithiasis / cholecystitis disproportionality consistent with rapid weight-loss biliary stasis; SURPASS-CVOT did not show increased pancreatitis vs dulaglutide. Compounded-product safety: FDA received >545 adverse-event reports linked to compounded tirzepatide through July 2025; approximately 10 deaths potentially associated with compounded GLP-1 RAs (combined sema + tirz, >1,150 combined reports).

Special populations. Pregnancy contraindicated for chronic weight management (Zepbound); used in T2D only if benefit outweighs risk. Lactation: insufficient human data. Pediatric: SURPASS-PEDS (T2D 10–18 y) met primary endpoint at EASD 2025; no pediatric label expansion. Elderly (≥65 y): no dose adjustment. Renal / hepatic impairment: no dose adjustment.

Suicidality. EMA PRAC concluded in 2024 class review (including tirzepatide) that available evidence does not establish causal association with suicidal ideation; FDA reached a similar conclusion January 2024; both agencies continue routine surveillance. No label change as of 2026-05-13.

Retraction status. No retractions identified for SURPASS, SURMOUNT, SUMMIT, SYNERGY-NASH, or SURMOUNT-OSA primary publications.

9. Drug Interactions

• Oral contraceptives: Single-dose tirzepatide reduces ethinylestradiol AUC by ~20% and norelgestromin AUC by ~21% via delayed gastric emptying; US label recommends switching to non-oral contraceptive or adding a barrier method for 4 weeks after initiation and after each dose escalation [Regulatory document — FDA labels].
• Insulin / sulfonylureas: Increased hypoglycemia risk; dose reduction of insulin or sulfonylurea recommended at initiation.
• Narrow-therapeutic-index oral agents: Class-level caution from delayed gastric emptying (levothyroxine, anticonvulsants); clinical relevance attenuates after first dose due to tachyphylaxis. Investigator-initiated metoprolol PK study underway [NCT06808802; no posted results].
• Warfarin: INR monitoring recommended around initiation / escalation; no clinically meaningful PK interaction in dedicated study.
• Acetaminophen / paracetamol: Delayed absorption observed; clinical relevance limited [Urva J Clin Pharmacol 2020] ⚠️.
• No CYP-based interactions expected (4.8 kDa peptide).

10. Research Gaps

1. Pediatric obesity. SURMOUNT-ADOLESCENTS-2 ongoing; no Phase 3 obesity readout in patients <18 y.
2. Pregnancy registries. No prospective registry readouts; Lilly post-marketing surveillance underway.
3. Head-to-head vs retatrutide. No published direct comparison (TRIUMPH-5 pending); only cross-trial inference.
4. Head-to-head vs CagriSema. No direct comparison; REDEFINE Phase 3 (Novo) pending peer review.
5. Long-term CV outcomes in obesity without diabetes. SURMOUNT-MMO event-driven; not expected before ~2027.
6. MASH Phase 3 outcomes (cirrhosis, liver-related events) — Phase 3 still recruiting.
7. Sustained efficacy after discontinuation. SURMOUNT-4 shows substantial regain; SURMOUNT-MAINTAIN dose-reduction strategy readout pending.
8. HFpEF confirmatory trial — required by FDA per Lilly’s May 2025 withdrawal.
9. Body composition / sarcopenia in older adults. No dedicated trial; reliance on DXA substudies of SURMOUNT.
10. Real-world cost-effectiveness and durability in low- / middle-income settings.
11. Sub-2.5 mg dose-response. No clinical-trial data for community-invented microdosing range.
12. Tirzepatide-specific characterization of anhedonia signal — anecdotal in the community; not a trial endpoint.
13. Tirzepatide-specific characterization of addictive-behavior reduction (alcohol, nicotine, cannabis) — community-widespread, preliminary trial literature only.

11. Bottom-Line Encyclopedia Note

Tirzepatide is an FDA- and EMA-approved once-weekly dual GIP / GLP-1 receptor co-agonist for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and moderate-to-severe obstructive sleep apnea in obese adults — the first drug approved for OSA in any population. As of 2026-05-13 the Phase 3 evidence base spans SURPASS (diabetes, including SURPASS-CVOT cardiovascular non-inferiority), SURMOUNT (obesity, including SURMOUNT-5 head-to-head superiority over semaglutide 2.4 mg at −20.2% vs −13.7%), SURMOUNT-OSA, SUMMIT (HFpEF), and SYNERGY-NASH (Phase 2 MASH). The US HFpEF label expansion was withdrawn in May 2025 pending a confirmatory trial. Common adverse events are gastrointestinal; pharmacovigilance signals for NAION and biliary disease remain under monitoring without formal label warnings. WADA placed tirzepatide on the 2026 Monitoring Program. All pivotal trials are Eli Lilly–funded.

11B. Gap Analysis — Where Science and Community Diverge

The Gap Analysis names where the two layers agree, disagree, and where one knows something the other doesn’t. This is the section most readers should consult before deciding.

Pattern: High community + High science = Convergent. Tirzepatide is the rare optimization-catalog substance where both layers are mature, the community arrived after the science (not before it), and the science still leads. The interesting gaps are not whether the drug works — both layers concur it does — but at the edges where community practice has extended beyond the trial population, and at one or two specific signals where one layer knows something the other does not.

Topic	Science Layer	Community Layer	Gap
Weight-loss efficacy in BMI ≥27 + comorbidity	−20.2% at 72 wk (SURMOUNT-5); head-to-head superior to semaglutide 2.4 mg	Aligned; consistent user reports	Convergent. Community arrived after the science.
Tirzepatide vs semaglutide	SURMOUNT-5 head-to-head: tirz superior on weight and waist; SURPASS-CVOT non-inferior to dulaglutide on MACE; no head-to-head MACE vs sema	Dominant view favors tirz on weight and tolerability; minority on r/Semaglutide flags sema’s longer track record and cleaner CV data (SELECT)	Largely convergent. Community split on CV reflects a real residual scientific gap.
Lean-mass loss	SURMOUNT DXA substudies show proportional to diet-induced loss; community-cited 26–40% lean-of-total figure is class-level, not tirzepatide-specific	Three camps: (a) habit problem fixed by protein + lifting (Layne Norton / Attia AMA #380 framing); (b) needs TRT cover in older men; (c) needs HGH / MK-677 stack	Partial convergence. Science supports camp (a) within trial conditions. Camps (b) and (c) extrapolate beyond evidence — no Phase 2/3 has tested tirz + TRT or tirz + HGH co-administration.
Microdosing (0.5–2 mg/wk)	No Phase 2/3 data below 2.5 mg. SURMOUNT-MAINTAIN tests dose reduction, not initiation microdose	Codified protocol with widespread community adoption	Subclassify: UNTESTED. Pharmacologically plausible by extrapolation; no clinical evidence for the dose range. Community ahead of science on practice; not validated as efficacy claim.
Tirzepatide → retatrutide cross-over	No clinical data on switching between approved tirz and investigational reta	Documented protocol on r/Peptides	UNTESTED. Speculative; depends on retatrutide’s own evidence base (B/60).
Off-label use in BMI <27, no comorbidity	Science score D / 10 — no Phase 3 in this population; effect size unknown	Sharply split: Attia refuses to prescribe below BMI 27; bodybuilding forums endorse	TESTED-NEGATIVE for trial eligibility / UNTESTED for efficacy. Community pushes through the gap; trial population specifically excludes this group.
Anhedonia signal	Not a trial endpoint; not characterized	Common community report; amplified by a small number of pseudonymous writers 🔴	Community-only signal, possibly real, untested. Subclassify: UNTESTED.
Alcohol / addictive-behavior reduction	Preliminary trial literature; no Phase 3 endpoint	Widespread community report (r/Mounjaro, r/Zepbound, r/loseit); Huberman has discussed mechanism	Community ahead of science on signal strength. Subclassify: TESTED-POSITIVE-PRELIMINARY. Likely real, magnitude uncharacterized.
NAION / optic-nerve signal	FAERS ROR 2.60; JAMA Netw Open 2025 cohort confirms differential risk vs other antidiabetics, smaller magnitude than for semaglutide; no label warning	Largely unaware	🔴 MAJOR GAP — community is unaware of an emerging safety signal that the science layer has flagged. Lower magnitude than for semaglutide, but real.
”Ozempic babies” / contraception interaction	Labeled: EE AUC −20%, norelgestromin AUC −21%; 4-week barrier-method guidance at initiation and each escalation	Common community report; understood as real	Convergent on the fact, partial on the mechanism. Community correctly identifies the phenomenon; partly attributes to fertility restoration (also true); some users miss the 4-week barrier window.
Compounded-product safety	FDA >545 adverse-event reports through July 2025; ~10 deaths potentially associated with compounded GLP-1 class	Split between “compounded was always sketchy” and “personalized 503A is equivalent”	Science layer has a hard data point the community contests. Compounded ≠ brand on the FDA record.
Rebound on discontinuation	SURMOUNT-4: +14% regain on placebo over 88 wk; SURMOUNT-MAINTAIN pending	Widespread community report; off-ramp protocols circulating but unvalidated	Convergent on the fact. Both layers blind on what reliably mitigates it.
WADA status	Not prohibited; 2026 Monitoring Program	Mostly unaware	Audience disconnect. Negligible for non-competing users; matters for tested athletes.
HFpEF use	Phase 3 SUMMIT positive but US sNDA withdrawn May 2025	Largely outside optimization-audience conversation	Therapeutic-only. Low community + High science cell for this indication. Approved-elsewhere question only.

Net characterisation. Tirzepatide sits in the convergent quadrant of the gap pattern matrix for its primary optimization-audience indication (obesity), with the community having largely arrived after the science and downstream of it. The most consequential gaps are:

1. Microdosing is untested at the doses (0.5–2 mg/wk) the community runs.
2. Off-label BMI <27 use is untested at the population the community runs it in.
3. NAION is a science-flagged signal the community has not absorbed.
4. Compounded ≠ brand on the FDA adverse-event record; the community is internally split on this, and the split has a hard data anchor.

12. Three Paths

You choose your risk tolerance. This monograph provides the data, not the recommendation.

Conservative path — prescription, on-label. Defined as: tirzepatide for a labeled indication (T2D, obesity BMI ≥30 or BMI ≥27 + weight-related comorbidity, OSA in obese adults) via brand product (Mounjaro or Zepbound), prescribed and titrated by a physician, with the labeled monitoring cadence and the labeled escalation schedule. Standard pre-treatment workup: HbA1c, lipid panel, ALT/AST/GGT, lipase, basic metabolic panel, TSH, MTC family-history screening; on-treatment review at each escalation, then quarterly to annually depending on indication. Off-cycle decisions follow physician guidance. All four conservative gates (peer-reviewed Phase 3 publication ✓, regulatory approval in ≥1 major jurisdiction ✓, independent clinical replication ✓ via RWE, long-term outcomes data — partially ✓ via SURPASS-CVOT, pending for obesity via SURMOUNT-MMO) are substantially met for T2D and obesity. Tirzepatide is one of the few catalog compounds where the conservative path is actually a path, not a hold.

Moderate path — prescription with off-label flexibility. Defined as: prescribed and supervised tirzepatide but extended beyond the strict label envelope — for example, BMI 25–27 with a weight-related driver not strictly meeting the comorbidity definition; supraphysiological body-composition goals rather than disease management; or use of personalized 503A formulations (B3- or B6-added “non-copy” preparations) as a cost-management strategy. This path means: full pre-cycle bloodwork (as conservative, plus DXA or BIA baseline); on-cycle bloodwork every 8–12 weeks; resistance training and protein intake at the upper community-standard range (≥1.6 g/kg, common community target ≥1 g/lb of target body weight); awareness of the contraception window after each escalation; explicit awareness of the NAION pharmacovigilance signal and the indefinite-treatment-duration framing.

High-tolerance path — gray-market with mitigation. Defined as: research-peptide channel access acknowledging that (a) the product is not regulated for human use, (b) batch identity and potency are not guaranteed, (c) the FDA has logged hundreds of adverse-event reports linked to compounded tirzepatide, (d) the community-recommended top dose (15 mg) is the dose where the trial GI-AE and dose-discontinuation rate is highest, and (e) microdose protocols below 2.5 mg have no Phase 2/3 efficacy data. The community mitigation stack documented in Pass 2: third-party COA verification via Janoshik or similar for the specific vial 🔴; titration slower than the headline 4-weeks-per-step protocol; ceiling at the lowest effective dose rather than the headline 15 mg; structured bloodwork on the optimization-community schedule; pre-cycle dialogue with a physician willing to continue monitoring even where they have not prescribed; awareness that the post-March-2025 gray market has shrunk and quality variance has risen as the supply chain has been disrupted.

13. Key References

Scientific (Pass 1 layer — full citations in source file):

• Coskun T et al. Mol Metab 2018 — discovery, design, preclinical [Peer-reviewed preclinical] ⚠️
• Willard FS et al. JCI Insight 2020 — biased GIPR agonism [Peer-reviewed preclinical] ⚠️
• Sun B et al. Cell 2022 — cryo-EM structures [Peer-reviewed preclinical]
• Heise T et al. Lancet D&E 2022 — mechanistic / mixed-meal [Peer-reviewed human study]
• Jastreboff AM et al. NEJM 2022 (SURMOUNT-1); NCT04184622 [Peer-reviewed human study] ⚠️
• Frías JP et al. NEJM 2021 (SURPASS-2) [Peer-reviewed human study] ⚠️
• Rosenstock J et al. Lancet 2021 (SURPASS-1) [Peer-reviewed human study] ⚠️
• Ludvik B et al. Lancet 2021 (SURPASS-3) [Peer-reviewed human study] ⚠️
• Del Prato S et al. Lancet 2021 (SURPASS-4) [Peer-reviewed human study] ⚠️
• Dahl D et al. JAMA 2022 (SURPASS-5) [Peer-reviewed human study] ⚠️
• Garvey WT et al. Lancet 2023 (SURMOUNT-2) [Peer-reviewed human study] ⚠️
• Wadden TA et al. Nat Med 2023 (SURMOUNT-3) [Peer-reviewed human study] ⚠️
• Aronne LJ et al. JAMA 2024 (SURMOUNT-4) [Peer-reviewed human study] ⚠️
• Loomba R et al. NEJM 2024;391:299–310 (SYNERGY-NASH) [Peer-reviewed human study] ⚠️
• Malhotra A et al. NEJM 2024;391:1193 (SURMOUNT-OSA) [Peer-reviewed human study] ⚠️
• Packer M et al. NEJM 2024 (SUMMIT, HFpEF) [Peer-reviewed human study] ⚠️
• Borlaug BA et al. Nat Med 2024 (SUMMIT mechanistic) [Peer-reviewed human study] ⚠️
• Kramer CM et al. JACC 2025;85:699–706 (SUMMIT CMR) [Peer-reviewed human study] ⚠️
• Aronne LJ et al. NEJM 2025;393:26–36 (SURMOUNT-5 head-to-head) [Peer-reviewed human study] ⚠️
• Nicholls SJ et al. NEJM 2025;393:2409–2420 (SURPASS-CVOT); PMID 41406444 [Peer-reviewed human study] ⚠️
• Krüger N et al. Nat Med 2026;32:342–352 — Aetion / Brigham trial-emulation [Peer-reviewed human study, independent replication]
• Wang L et al. JAMA Netw Open 2025;8:e2526327 — NAION RWE [Peer-reviewed human study]
• FDA NDA 215866 (Mounjaro); FDA NDA 217806 (Zepbound) [Regulatory document]
• FDA Declaratory Order, tirzepatide shortage resolution 2024-12-19 [Regulatory document]
• OFA v. FDA, 4:24-cv-00953 N.D. Tex., 2025-05-07 [Regulatory / judicial]
• EMA EPAR EMEA/H/C/005620 (Mounjaro) [Regulatory document]
• WADA 2026 Monitoring Program (effective 2026-01-01) [Regulatory document]
• PubChem CID 156588324 [Academic secondary source]

Community (Pass 2 layer — full citations in source file):

• Peter Attia The Drive AMA #45 (Mar 13 2023) — first major optimization-audience framing of sema vs tirz; lean-mass focus
• Peter Attia The Drive AMA #64 (Oct 7 2024) — compounding-pharmacy guidance, retatrutide pipeline, oral / sublingual skepticism
• Peter Attia “Lean mass loss on GLP-1 receptor agonists” (Feb 18 2023) — foundational community sarcopenia text
• r/Mounjaro pinned megathreads (food noise, side effects, hair loss) — ongoing 2022–2026
• r/Zepbound (discontinuation, rebound, “Ozempic face”) — ongoing 2023–2026
• r/tirzepatidecompound (reconstitution math, microdose protocols) — 2023–2025
• r/Peptides and r/PeptideUmbrella (vendor reviews, Janoshik COA culture, tirz → reta cross-over) — 2024–2026
• Eli Lilly v. Alderwood Surgical Center et al., W.D. Wash. 2:24-cv-00878 (motion to dismiss survived 2025-03-07) — compounding-litigation anchor
• Empower Pharmacy product pages — 503A personalized formulations ⚠️
• Compoundproviders.com / Emerge — pricing aggregator ⚠️
• Roidly bodybuilding writeup (Mar 11 2026) — “Clen replacement” framing ⚠️
• Athlean-X / Layne Norton content — community-cited lean-mass-of-total-loss range

14. Audit / Refresh Trail

• Composed: 13 May 2026
• Science-layer source: tirzepatide_sci_2026-05-13_S95.md (Pass 1; refreshed 2026-05-13 against prior 2026-05-11 baseline)
• Community-layer source: tirzepatide_com_2026-05-13_C81.md (Pass 2)
• Next refresh triggers: (a) SURMOUNT-MMO top-line (~2027-10); (b) SURMOUNT-MAINTAIN readout (~mid-2026); (c) SURPASS-PEDS peer-reviewed publication; (d) any FDA / EMA label addition for NAION; (e) HFpEF confirmatory-trial registration or readout; (f) Cochrane SR publication specific to tirzepatide; (g) regulatory action on the “personalized 503A” workaround (Lilly v. Alderwood progression); (h) any retraction of cited primary literature; (i) head-to-head readout vs retatrutide (TRIUMPH-5) or CagriSema; (j) vendor-landscape shift (Janoshik scandal, major compounded-product safety event, gray-market enforcement).